Dermatology · Dearborn, MI
NPI
1467611475
Since 2008
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
18100 Oakwood Blvd, Suite 300
Dearborn, MI, 48124
Phone (313) 240-4900
Groups this clinician bills Medicare through
Medicare paid, 2024
$27K
635 services
Medicare patients, 2024
184
Average age 67
Drug cost, 2024
$1.2M
895 prescriptions
Company payments, 2025
$121K
From 33 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Steven D Daveluy was code 17003 (destruction skin lesion), 115 times for 18 patients. In total Steven D Daveluy billed 635 services in 46 codes, and Medicare paid $27K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-12-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 115 | 18 | $4.80 | $552 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 63 | 13 | $0.79 | $49.88 |
| 99214 Office E&M - Established | Office | 60 | 44 | $85.54 | $5,132 |
| 99213 Office E&M - Established | Office | 56 | 45 | $59.46 | $3,330 |
| 17000 Destruction Skin Lesion | Office | 30 | 25 | $36.78 | $1,103 |
| 17110 Destruction Skin Lesion | Office | 30 | 24 | $74.05 | $2,221 |
| 11102 Skin Biopsy | Office | 23 | 22 | $62.88 | $1,446 |
| 99213 Office E&M - Established | Facility | 23 | 18 | $43.82 | $1,008 |
| 11900 Skin | Office | 20 | 11 | $39.36 | $787 |
| 99214 Office E&M - Established | Facility | 19 | 14 | $66.13 | $1,256 |
| 99203 Office E&M - New | Office | 18 | 18 | $50.27 | $905 |
| 99204 Office E&M - New | Office | 16 | 16 | $128.53 | $2,056 |
| 99221 Hospital E&M - Initial | Facility | 12 | 12 | $58.80 | $706 |
By year: 2022 $39K for 731 services; 2023 $37K for 833 services; 2024 $27K for 635 services.
Medicare prescription drug claims, 2024
In 2024, the drug Steven D Daveluy prescribed most often to Medicare patients was Clobetasol Propionate, with 183 prescriptions and refills. In total Steven D Daveluy wrote 895 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Clobetasol Propionate Generic | 183 | 188 | 52 | $6,771 |
| Triamcinolone Acetonide Generic | 146 | 169 | 57 | $2,416 |
| Ketoconazole Generic | 105 | 105 | 30 | $1,729 |
| Ammonium Lactate Generic | 43 | 51 | 24 | $1,049 |
| Hydrocortisone Generic | 36 | 37 | 15 | $111 |
| Clindamycin Phosphate Generic | 28 | 28 | 11 | $629 |
| Dupixent Pen Dupilumab | 28 | 28 | Under 11 | $107K |
| Imiquimod Generic | 27 | 32 | Under 11 | $15K |
| Betamethasone Dipropionate Generic | 25 | 26 | Under 11 | $1,637 |
| Humira(Cf) Pen Adalimumab | 25 | 26 | Under 11 | $335K |
| Doxycycline Monohydrate Generic | 19 | 19 | Under 11 | $364 |
| Timolol Maleate Generic | 14 | 20 | Under 11 | $12K |
| Cosentyx Unoready Pen Secukinumab | 14 | 16 | Under 11 | $135K |
| Taltz Autoinjector Ixekizumab | 13 | 13 | Under 11 | $85K |
| Valchlor Mechlorethamine Hcl | 11 | 11 | Under 11 | $69K |
Brand drugs: 150 claims; generic drugs: 745 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Steven D Daveluy $121K ($121K in general payments such as food, travel and fees and $713 for research) from 33 companies. The largest payer was UCB, Inc. with $55K.
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. UCB.BR | 67 | $55K |
| Incyte Corporation INCY | 18 | $18K |
| Novartis Pharmaceuticals Corporation NVS | 21 | $13K |
| Abbvie Inc. ABBV | 17 | $12K |
| Genzyme Corporation SNY | 11 | $8,909 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $5,746 |
| Sanofi US Services Inc. SNY | 3 | $2,598 |
| Ucb Sa UCB.BR | 8 | $1,845 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 8 | $1,358 |
| Insmed, Inc. INSM | 8 | $1,183 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.